Sensorion SA

ALSEN

Company Profile

  • Business description

    Sensorion SA is a France-based clinical-stage biotech company dedicated to developing therapies to restore, treat, and prevent hearing loss. The company's product is in phase 2a clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies. The Company does business in a single operating segment: conducting research and development to discover drugs to treat inner ear disorders with a view to their future marketing. The company's pipeline programs are SENS-401 SSNHL, SENS-401 CIO, GJB2-GT, GJB2-GT, SENS-401 Cochlear, and others.

  • Contact

    375, rue du Professeur Joseph Blayac
    Montpellier34080
    FRA

    T: +33 467207730

    https://www.sensorion.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    57

Stocks News & Analysis

stocks

Another incredible quarter from Microsoft

We were wrong when we thought last quarter would be hard to top.
stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,916.0083.00-0.92%
CAC 407,771.9789.99-1.14%
DAX 4024,065.47196.75-0.81%
Dow JONES (US)44,130.98330.30-0.74%
FTSE 1009,132.814.13-0.05%
HKSE24,773.33403.60-1.60%
NASDAQ21,122.457.23-0.03%
Nikkei 22540,655.21414.61-1.01%
NZX 50 Index12,774.8148.93-0.38%
S&P 5006,339.3923.51-0.37%
S&P/ASX 2008,659.1083.70-0.96%
SSE Composite Index3,573.2142.51-1.18%

Market Movers